CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival
- PMID: 26552959
- DOI: 10.1038/nrclinonc.2015.207
CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival
Erratum for
-
Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.Nat Rev Clin Oncol. 2015 Nov;12(11):621. doi: 10.1038/nrclinonc.2015.178. Epub 2015 Oct 13. Nat Rev Clin Oncol. 2015. PMID: 26462125 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources